CoChat
Sign Up
Cited by 60

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins

Chadarevian, Jean Paul, Davtyan, Hayk, Chadarevian, Alina L., Nguyen, Jasmine, Capocchi, Joia K., Le, Lauren, Escobar, Adrian, Chadarevian, Talar, Mansour, Kimiya, Deynega, Ekaterina, Mgerian, Michael, Tu, Christina, Kiani Shabestari, Sepideh, Carlen-Jones, William, Eskandari-Sedighi, Ghazaleh, Hasselmann, Jonathan, Spitale, Robert C., Blurton-Jones, Mathew·2025·Cell Stem Cell
DOI 10.1016/j.stem.2025.03.009PMC PMC12360426
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2025.03.009

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 121

  1. Profaci, 2020, The blood-brain barrier in health and disease: Important unanswered questions, J. Exp. Med., 217, 10.1084/jem.20190062 · DOI
  2. Pardridge, 2005, The blood-brain barrier: bottleneck in brain drug development, Neurorx, 2, 3, 10.1602/neurorx.2.1.3 · DOI · Paper page
  3. Chew, 2023, CD98hc is a target for brain delivery of biotherapeutics, Nat. Commun., 14
  4. Zuchero, 2016, Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies, Neuron, 89, 70, 10.1016/j.neuron.2015.11.024 · DOI
  5. Grimm, 2023, Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans, mAbs, 15, 10.1080/19420862.2023.2261509 · DOI
  6. Freskgård, 2017, Antibody therapies in CNS diseases, Neuropharmacology, 120, 38, 10.1016/j.neuropharm.2016.03.014 · DOI
  7. van Lengerich, 2023, A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models, Nat. Neurosci., 26, 416
  8. Pulgar, 2018, Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges, Front. Neurosci., 12, 1019, 10.3389/fnins.2018.01019 · DOI · Paper page
  9. Sorrentino, 2016, Brain Targeting in MPS-IIIA, Pediatr. Endocrinol. Rev., 13, 630
  10. Wijburg, 2021, A multicenter open-label extension study of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A, Mol. Genet. Metab., 134, 175, 10.1016/j.ymgme.2021.07.001 · DOI
  11. Stone, 2025, Adeno-associated virus vectors and neurotoxicity-lessons from preclinical and human studies, Gene Ther., 32, 60, 10.1038/s41434-023-00405-1 · DOI
  12. Bellettato, 2018, Possible strategies to cross the blood-brain barrier, Ital. J. Pediatr., 44, 10.1186/s13052-018-0563-0 · DOI
  13. Prasad, 2022, Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches, Hum. Gene Ther., 33, 1228, 10.1089/hum.2022.138 · DOI · Paper page
  14. Amado, 2019, AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity, Mol. Ther., 27, 465, 10.1016/j.ymthe.2018.11.013 · DOI
  15. Liu, 2023, Transplanting Human Neural Stem Cells with ≈50% Reduction of SOX9 Gene Dosage Promotes Tissue Repair and Functional Recovery from Severe Spinal Cord Injury, Adv. Sci. (Weinh), 10
  16. Mooney, 2018, Concise Review: Neural Stem Cell-Mediated Targeted Cancer Therapies, Stem Cells Transl. Med., 7, 740, 10.1002/sctm.18-0003 · DOI
  17. Blurton-Jones, 2014, Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models, Stem Cell Res. Ther., 5, 10.1186/scrt440 · DOI
  18. Amariglio, 2009, Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient, PLoS Med., 6, 10.1371/journal.pmed.1000029 · DOI
  19. Marsh, 2017, HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease, Stem Cell Rep., 8, 235, 10.1016/j.stemcr.2016.12.019 · DOI
  20. Matarredona, 2019, Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells. Therapeutic Implications, Front. Oncol., 9, 10.3389/fonc.2019.00779 · DOI
  21. Abud, 2017, iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases, Neuron, 94, 278, 10.1016/j.neuron.2017.03.042 · DOI · Paper page
  22. Hasselmann, 2019, Development of a Chimeric Model to Study and Manipulate Human Microglia In Vivo, Neuron, 103, 1016, 10.1016/j.neuron.2019.07.002 · DOI · Paper page
  23. Liu, 2012, Developmental origins of brain tumors, Curr. Opin. Neurobiol., 22, 844, 10.1016/j.conb.2012.04.012 · DOI
  24. Zong, 2015, Cell of origin for malignant gliomas and its implication in therapeutic development, Cold Spring Harb. Perspect. Biol., 7, 10.1101/cshperspect.a020610 · DOI
  25. Azzarelli, 2018, The developmental origin of brain tumours: a cellular and molecular framework, Development, 145, 10.1242/dev.162693 · DOI
  26. Sun, 2023, Human microglial state dynamics in Alzheimer's disease progression, Cell, 186, 4386, 10.1016/j.cell.2023.08.037 · DOI · Paper page
  27. Swanson, 2023, Microglial CD68 and L-ferritin upregulation in response to phosphorylated-TDP-43 pathology in the amyotrophic lateral sclerosis brain, Acta Neuropathol. Commun., 11, 10.1186/s40478-023-01561-6 · DOI
  28. Woollacott, 2020, Microglial burden, activation and dystrophy patterns in frontotemporal lobar degeneration, J. Neuroinflammation, 17, 10.1186/s12974-020-01907-0 · DOI
  29. Barclay, 2024, An inducible genetic tool to track and manipulate specific microglial states reveals their plasticity and roles in remyelination, Immunity, 57, 1394, 10.1016/j.immuni.2024.05.005 · DOI · Paper page
  30. Dolan, 2023, Exposure of iPSC-derived human microglia to brain substrates enables the generation and manipulation of diverse transcriptional states in vitro, Nat. Immunol., 24, 1382, 10.1038/s41590-023-01558-2 · DOI · Paper page
  31. Keren-Shaul, 2017, A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease, Cell, 169, 1276, 10.1016/j.cell.2017.05.018 · DOI · Paper page
  32. Visan, 2017, Alzheimer's disease microglia, Nat. Immunol., 18, 10.1038/ni.3802 · DOI
  33. Rojo, 2019, Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations, Nat. Commun., 10, 10.1038/s41467-019-11053-8 · DOI
  34. Grimm, 2013, Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer's Disease, Front. Aging Neurosci., 5, 10.3389/fnagi.2013.00098 · DOI
  35. Chadarevian, 2023, Engineering an inhibitor-resistant human CSF1R variant for microglia replacement, J. Exp. Med., 220, 10.1084/jem.20220857 · DOI
  36. Kayed, 2013, Molecular mechanisms of amyloid oligomers toxicity, J. Alzheimers Dis., 33, S67, 10.3233/JAD-2012-129001 · DOI
  37. Subramanian, 2020, Synaptic Loss in Alzheimer's Disease: Mechanistic Insights Provided by Two-Photon, Front. Cell. Neurosci., 14, 10.3389/fncel.2020.592607 · DOI
  38. Terry, 1991, Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment, Ann. Neurol., 30, 572, 10.1002/ana.410300410 · DOI · Paper page
  39. de Wilde, 2016, Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability, Alzheimers Dement., 12, 633, 10.1016/j.jalz.2015.12.005 · DOI
  40. Campbell, 2018, Neprilysin Inhibitors and Bradykinin, Front. Med. (Lausanne), 5
  41. Watamura, 2022, Somatostatin-evoked Aβ catabolism in the brain: Mechanistic involvement of α-endosulfine-KATP channel pathway, Mol. Psychiatry, 27, 1816, 10.1038/s41380-021-01368-8 · DOI
  42. Chadarevian, 2023, CRISPR generation of CSF1R-G795A human microglia for robust microglia replacement in a chimeric mouse model, Star Protoc., 4, 10.1016/j.xpro.2023.102490 · DOI
  43. Tolar, 2021, Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression, Int. J. Mol. Sci., 22, 10.3390/ijms22126355 · DOI
  44. Bader, 2023, Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice, Life (Basel), 13
  45. Franco-Bocanegra, 2021, Microglial morphology in Alzheimer's disease and after Aβ immunotherapy, Sci. Rep., 11, 10.1038/s41598-021-95535-0 · DOI
  46. St-Pierre, 2022, Ultrastructural characterization of dark microglia during aging in a mouse model of Alzheimer's disease pathology and in human post-mortem brain samples, J. Neuroinflammation., 19, 10.1186/s12974-022-02595-8 · DOI
  47. Doorn, 2014, Increased amoeboid microglial density in the olfactory bulb of Parkinson's and Alzheimer's patients, Brain pathol, 24, 152, 10.1111/bpa.12088 · DOI
  48. Wetering, 2024, Neuroinflammation is associated with Alzheimer’s disease co-pathology in dementia with Lewy bodies, Acta Neuropathol. Commun., 12
  49. Baek, 2024, Advanced Immunolabeling Method for Optical Volumetric Imaging Reveals Dystrophic Neurites of Dopaminergic Neurons in Alzheimer's Disease Mouse Brain, Mol. Neurobiol., 61, 3976, 10.1007/s12035-023-03823-9 · DOI
  50. Hassiotis, 2018, Lysosomal LAMP1 immunoreactivity exists in both diffuse and neuritic amyloid plaques in the human hippocampus, Eur. J. Neurosci, 47, 1043, 10.1111/ejn.13913 · DOI · Paper page
  51. Gowrishankar, 2015, Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques, Proc. Natl. Acad. Sci. USA, 112, E3699, 10.1073/pnas.1510329112 · DOI · Paper page
  52. Akiyama, 2001, Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition, Brain Res., 902, 277, 10.1016/S0006-8993(01)02390-3 · DOI
  53. Fukami, 2002, Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology, Neurosci. Res., 43, 39, 10.1016/S0168-0102(02)00015-9 · DOI · Paper page
  54. Iwata, 2004, Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain, J. Neurosci, 24, 991, 10.1523/JNEUROSCI.4792-03.2004 · DOI
  55. Mabrouk, 2023, Most dystrophic neurites in the common 5xFAD Alzheimer mouse model originate from axon terminals, Neurobiol. Dis., 182, 10.1016/j.nbd.2023.106150 · DOI · Paper page
  56. Forner, 2021, Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease, Sci. Data, 8, 10.1038/s41597-021-01054-y · DOI · Paper page
  57. Kandalepas, 2013, The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques, Acta Neuropathol., 126
  58. Scarlett, 2022, The "Loss" of Perineuronal Nets in Alzheimer's Disease: Missing or Hiding in Plain Sight?, Front. Integr. Neurosci., 16, 10.3389/fnint.2022.896400 · DOI · Paper page
  59. Crapser, 2020, Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain, EBiomedicine, 58, 10.1016/j.ebiom.2020.102919 · DOI · Paper page
  60. Zhang, 2024, Decreased extrasynaptic δ-GABA_A receptors in PNN-associated parvalbumin interneurons correlates with anxiety in APP and tau mouse models of Alzheimer's disease, Br. J. Pharmacol, 181, 3944, 10.1111/bph.16441 · DOI
  61. Sanchez-Mico, 2021, Amyloid-β impairs the phagocytosis of dystrophic synapses by astrocytes in Alzheimer's disease, Glia, 69, 997, 10.1002/glia.23943 · DOI · Paper page
  62. Tewari, 2024, Astrocytes require perineuronal nets to maintain synaptic homeostasis in mice, Nat. Neurosci., 27, 1475, 10.1038/s41593-024-01714-3 · DOI
  63. Kurucu, 2022, Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer's disease, Eur. J. Neurol., 29, 1311, 10.1111/ene.15043 · DOI
  64. Brun, 1995, Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration, Neurodegeneration, 4, 171, 10.1006/neur.1995.0021 · DOI
  65. Leng, 2021, Molecular characterization of selectively vulnerable neurons in Alzheimer's disease, Nat. Neurosci., 24, 276, 10.1038/s41593-020-00764-7 · DOI · Paper page
  66. Sahrai, 2023, SIMOA-based analysis of plasma NFL levels in MCI and AD patients: a systematic review and meta-analysis, BMC Neurol., 23, 10.1186/s12883-023-03377-2 · DOI
  67. Park, 2022, Diagnostic Blood Biomarkers in Alzheimer's Disease, Biomedicines, 10, 10.3390/biomedicines10010169 · DOI
  68. Giacomucci, 2022, Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment, J. Neurol., 269, 4270, 10.1007/s00415-022-11055-5 · DOI
  69. Akiyama, 2000, Inflammation and Alzheimer's disease, Neurobiol. Aging, 21, 383, 10.1016/S0197-4580(00)00124-X · DOI · Paper page
  70. Heneka, 2015, Neuroinflammation in Alzheimer's disease, Lancet Neurol., 14, 388, 10.1016/S1474-4422(15)70016-5 · DOI · Paper page
  71. Foley, 2024, Alzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK-ADRC cohort, Alzheimers Dement., 20, 1374, 10.1002/alz.13485 · DOI
  72. Lu, 2023, Advances in the study of IL-17 in neurological diseases and mental disorders, Front. Neurol., 14, 10.3389/fneur.2023.1284304 · DOI
  73. Brigas, 2021, IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease, Cell Rep., 36, 10.1016/j.celrep.2021.109574 · DOI
  74. Cao, 2023, IL-17A promotes the progression of Alzheimer's disease in APP/PS1 mice, Immun. Ageing, 20, 10.1186/s12979-023-00397-x · DOI
  75. Zhang, 2016, Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse, Neuron, 89, 37, 10.1016/j.neuron.2015.11.013 · DOI · Paper page
  76. Patani, 2023, Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration, Nat. Rev. Neurol., 19, 395, 10.1038/s41582-023-00822-1 · DOI · Paper page
  77. Saraste, 2023, Association of serum neurofilament light with microglial activation in multiple sclerosis, J. Neurol. Neurosurg. Psychiatry, 94, 698, 10.1136/jnnp-2023-331051 · DOI · Paper page
  78. Thakur, 2023, Neuroinflammation in Alzheimer's Disease: Current Progress in Molecular Signaling and Therapeutics, Inflammation, 46, 1, 10.1007/s10753-022-01721-1 · DOI · Paper page
  79. Si, 2023, Targeting neuroinflammation in Alzheimer's disease: from mechanisms to clinical applications, Neural Regen. Res., 18, 708, 10.4103/1673-5374.353484 · DOI
  80. Song, 2023, Single-cell sequencing reveals the landscape of the human brain metastatic microenvironment, Commun. Biol., 6, 10.1038/s42003-023-05124-2 · DOI
  81. Álvarez-Prado, 2023, Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors, Cell Rep. Med., 4
  82. Karimi, 2023, Single-cell spatial immune landscapes of primary and metastatic brain tumours, Nature, 614, 555, 10.1038/s41586-022-05680-3 · DOI
  83. Evans, 2023, Microglia promote anti-tumour immunity and suppress breast cancer brain metastasis, Nat. Cell Biol., 25, 1848, 10.1038/s41556-023-01273-y · DOI
  84. Zhang, 2019, The Spatial and Temporal Characters of Demyelination and Remyelination in the Cuprizone Animal Model, Anat. Rec. (Hoboken), 302, 2020, 10.1002/ar.24216 · DOI
  85. Beecken, 2023, The Cuprizone Mouse Model: A Comparative Study of Cuprizone Formulations from Different Manufacturers, Int. J. Mol. Sci., 24, 10.3390/ijms241310564 · DOI
  86. van der Poel, 2019, Transcriptional profiling of human microglia reveals grey-white matter heterogeneity and multiple sclerosis-associated changes, Nat. Commun., 10, 10.1038/s41467-019-08976-7 · DOI · Paper page
  87. van den Bosch, 2024, Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation, Nat. Commun., 15, 10.1038/s41467-024-46068-3 · DOI
  88. Papadopoulos, 2009, Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis, Brain Pathol., 19, 238, 10.1111/j.1750-3639.2008.00177.x · DOI · Paper page
  89. Geurts, 2007, Extensive hippocampal demyelination in multiple sclerosis, J. Neuropathol. Exp. Neurol., 66, 819, 10.1097/nen.0b013e3181461f54 · DOI
  90. Hildebrandt, 2006, Memory performance in multiple sclerosis patients correlates with central brain atrophy, Mult. Scler., 12, 428, 10.1191/1352458506ms1286oa · DOI
  91. Longoni, 2015, Deficits in memory and visuospatial learning correlate with regional hippocampal atrophy in MS, Brain Struct. Funct., 220, 435, 10.1007/s00429-013-0665-9 · DOI
  92. Sikanyika, 2019, Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease, Neurochem. Res., 44, 1289, 10.1007/s11064-019-02756-x · DOI
  93. Park, 2013, Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice, Brain Res., 1529, 113, 10.1016/j.brainres.2013.05.045 · DOI
  94. Nalivaeva, 2012, The Alzheimer's amyloid-degrading peptidase, neprilysin: can we control it?, Int. J. Alzheimers Dis., 2012
  95. Miners, 2011, Aβ-degrading enzymes: potential for treatment of Alzheimer disease, J. Neuropathol. Exp. Neurol., 70, 944, 10.1097/NEN.0b013e3182345e46 · DOI · Paper page
  96. Wang, 2005, Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging, J. Neuropathol. Exp. Neurol., 64, 378, 10.1093/jnen/64.5.378 · DOI
  97. Carpentier, 2002, Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy, J. Neuropathol. Exp. Neurol., 61, 849, 10.1093/jnen/61.10.849 · DOI
  98. Yasojima, 2001, Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide, Neurosci. Lett., 297, 97, 10.1016/S0304-3940(00)01675-X · DOI
  99. Wang, 2016, Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese, Mol. Neurobiol., 53, 4883, 10.1007/s12035-015-9411-z · DOI
  100. Chen, 2021, The Association between Neprilysin gene polymorphisms and Alzheimer's disease in Tibetan population, Brain Behav., 11, 10.1002/brb3.2002 · DOI
  101. Lebson, 2010, Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice, J. Neurosci., 30, 9651, 10.1523/JNEUROSCI.0329-10.2010 · DOI
  102. Meilandt, 2009, Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice, J. Neurosci., 29, 1977, 10.1523/JNEUROSCI.2984-08.2009 · DOI
  103. Rofo, 2022, Blood-brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease, Alzheimers Res. Ther., 14, 10.1186/s13195-022-01132-2 · DOI
  104. Salvadores, 2022, Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer's disease, Acta Neuropathol. Commun., 10, 10.1186/s40478-022-01332-9 · DOI
  105. Shin, 2019, Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation, Alzheimers Res. Ther., 11, 10.1186/s13195-019-0541-9 · DOI
  106. Wilcox, 2011, Aβ oligomer-induced synapse degeneration in Alzheimer's disease, Cell. Mol. Neurobiol., 31, 939, 10.1007/s10571-011-9691-4 · DOI
  107. Huang, 2006, Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function, J. Biol. Chem., 281, 17941, 10.1074/jbc.M601372200 · DOI
  108. Ackley, 2021, Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis, BMJ, 372
  109. Mullane, 2020, Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?, Biochem. Pharmacol., 177, 10.1016/j.bcp.2020.113945 · DOI
  110. Kanemitsu, 2003, Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form, Neurosci. Lett., 350, 113, 10.1016/S0304-3940(03)00898-X · DOI
  111. Claeys, 2023, Limitations of PLX3397 as a microglial investigational tool: Peripheral and off-target effects dictate the response to inflammation, Front. Immunol., 14, 10.3389/fimmu.2023.1283711 · DOI
  112. Boyd, 2021, Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes, J. Neuroinflammation, 18, 67, 10.1186/s12974-021-02118-x · DOI
  113. Liu, 2019, Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo, Exp. Neurol., 318, 32, 10.1016/j.expneurol.2019.04.011 · DOI · Paper page
  114. Zhou, 2022, Microglial debris is cleared by astrocytes via C4b-facilitated phagocytosis and degraded via RUBICON-dependent noncanonical autophagy in mice, Nat. Commun., 13, 10.1038/s41467-022-33932-3 · DOI
  115. Shibuya, 2022, Treatment of a genetic brain disease by CNS-wide microglia replacement, Sci. Transl. Med., 14, 10.1126/scitranslmed.abl9945 · DOI
  116. Wood, 2022, Delivering gene therapy for mucopolysaccharide diseases, Front. Mol. Biosci., 9, 10.3389/fmolb.2022.965089 · DOI
  117. Shemer, 2018, Engrafted parenchymal brain macrophages differ from microglia in transcriptome, chromatin landscape and response to challenge, Nat. Commun., 9, 10.1038/s41467-018-07548-5 · DOI · Paper page
  118. Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 10.1186/s13059-014-0550-8 · DOI · Paper page
  119. Bray, 2016, Near-optimal probabilistic RNA-seq quantification, Nat. Biotechnol., 34, 525, 10.1038/nbt.3519 · DOI · Paper page
  120. Soneson, 2015, Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences, F1000Res, 4, 10.12688/f1000research.7563.1 · DOI · Paper page
  121. Davtyan, 2019, Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice, Alzheimers Res. Ther., 11, 10.1186/s13195-019-0556-2 · DOI · Paper page

Cited by

Sorted by citations

See all 60

Metadata

Authors
Chadarevian, J. P., Davtyan, H., Chadarevian, A. L., Nguyen, J., Capocchi, J. K., Le, L., Escobar, A., Chadarevian, T., Mansour, K., Deynega, E., Mgerian, M., Tu, C., Kiani Shabestari, S., Carlen-Jones, W., Eskandari-Sedighi, G., Hasselmann, J., Spitale, R. C., & Blurton-Jones, M.
ORCID
Blurton-Jones, Mathew
Venue
Cell Stem Cell
Publisher
Elsevier BV
Published
2025-06
Volume
32
Issue
6
Pages
914-934.e8
ISSN
1934-5909
DOI
10.1016/j.stem.2025.03.009
PMC
PMC12360426
Cited by
60
References
36
Language
en
Licence
Funders
  • Alzheimer Society of Canada
  • Cure Alzheimer's Fund (DA048813)
  • Larry L. Hillblom Foundation (AG066519, 2024-A-023-FEL, AG06970101)
  • California Institute of Regenerative Medicine (EDUCA4-12822, RT3-07893)
  • National Institutes of Health
  • California Institute for Regenerative Medicine
  • National Institute on Drug Abuse (DA048813)
  • National Institute on Aging (AG061895, T32 AG00096, T32 AG073088)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review